We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
story of the week
Published in Oncology

Journal Scan / Research · October 09, 2019

Encorafenib, Binimetinib, and Cetuximab in BRAF V600E–Mutated Colorectal Cancer

The New England Journal of Medicine


Additional Info

Disclosure statements are available on the authors' profiles:

The New England Journal of Medicine
Encorafenib, Binimetinib, and Cetuximab in BRAF V600E-Mutated Colorectal Cancer
N. Engl. J. Med 2019 Sep 30;[EPub Ahead of Print], S Kopetz, A Grothey, R Yaeger, E Van Cutsem, J Desai, T Yoshino, H Wasan, F Ciardiello, F Loupakis, YS Hong, N Steeghs, TK Guren, HT Arkenau, P Garcia-Alfonso, P Pfeiffer, S Orlov, S Lonardi, E Elez, TW Kim, JHM Schellens, C Guo, A Krishnan, J Dekervel, V Morris, A Calvo Ferrandiz, LS Tarpgaard, M Braun, A Gollerkeri, C Keir, K Maharry, M Pickard, J Christy-Bittel, L Anderson, V Sandor, J Tabernero

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading